• Prepare for the
impending first-to-file regime and decide whether to file under the old or new
• Analyze the outcome in Prometheus and its impact on personalized medicine;
• Determine the implications of the Myriad case for subject matter patentability;
• Design systems to rapidly respond to new post-grant and inter partes review procedures;
• Explore ways in which the Therasense decision has changed how patent attorneys approach inequitable conduct concerns;
• Utilize superior techniques to better protect antibodies and immunological innovations;
• Scrutinize the recently issued biosimilars pathway regulations and craft a winning biologic patenting strategy; and
• Assess how the combined evolution of prior art obviousness and obvious-type double patenting are influencing the future of secondary patents.
• USPTO keynote: A
primer on the USPTO's efforts to implement the America Invents Act -- to be
presented by Teresa Stanek Rea, Deputy Director of the U.S. Patent &
• The sky is not falling: Protecting your IP after Prometheus and Myriad;
• Scrutinizing the CAFC'S decisions in Akamai and McKesson and protecting technology in their wake;
• The complete guide to formulating a biosimilars patent strategy following the implementation of the FDA's approval pathway;
• Overcoming the challenges and grasping the opportunities presented by the PTO's new post-grant review and inter partes review procedures;
• Understanding the obligations and defenses afforded biotech patent attorneys post-Therasense -- to be presented in part by Patent Docs author Dr. Kevin Noonan of McDonnell, Boehnen, Hulbert & Berghoff LLP;
• Producing a robust written description to satisfy ever-shifting requirements and ensure patent validity;
• Crafting a global strategy: Best practices for international prosecution and litigation to maximize the value of your biotech patent portfolio; and
• Demystifying the current obviousness standard and its implications for biotech patenting.
An interactive working group session entitled: "Integrating Changes at the PTO into Biotech Patent Practices" will be offered from 9:00 am to 12:00 pm on November 28, 2012. A post-conference master class entitled: "Successful and Practical Strategies for Patenting Antibodies" will be offered from 9:00 am to 12:00 pm on November 30, 2012.
The agenda for the Biotech Patents conference can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee is $2,295 (conference alone), $2,995 (conference plus group session or master class), or $3,495 (conference, group session, and master class). Those registering on or before September 27, 2012 will receive a $300 discount and those registering by October 26, 2012 will receive a $200 discount. Patent Docs readers who reference the discount code "PD 200" will receive $200 off the current price tier when registering. Those interested in registering for the conference can do so here, by e-mailing [email protected] calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of ACI's Biotech Patents conference.